Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Summary on May 17, 2018

May 17, 2018 - By Richard Slagle

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.16. That’s change of 0.19, from 2017Q3’s 1.35. 7 investors sold all, 12 reduced holdings as Regulus Therapeutics Inc. ratio is negative. 12 grew stakes while 10 funds amassed stakes. Funds hold 53.17 million shares thus 9.64% less from 2017Q3’s 58.85 million shares.
Nea Management Company Ltd Limited Liability Company has invested 0.47% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS). Morgan Stanley accumulated 2,872 shs. Point72 Asset Lp reported 0.01% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Wells Fargo Company Mn invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). 13.97M are held by Bvf Inc Il. Millennium Management Ltd Llc holds 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 424,400 shs. Geode Mngmt Ltd Llc holds 483,951 shs. South Dakota Investment Council invested in 0.04% or 1.78 million shs. Hightower holds 21,200 shs. Ascend Cap Ltd Llc holds 0.04% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 1.01 million shs. Quantitative Inv Management Ltd Liability Company reported 45,800 shs. Bnp Paribas Arbitrage stated it has 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Blackrock Inc invested in 818,004 shs. Rhenman Partners Asset Mgmt reported 492,878 shs. D E Shaw Co reported 27,319 shs.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

A total of 5 analysts rate Regulus (NASDAQ:RGLS) as follows: 2 “Buy”, 3 “Hold” and 0 “Sell”. Тherefore 40% are bullish. (NASDAQ:RGLS) has 8 ratings reports on May 17, 2018 according to StockzIntelligence. The company rating was maintained by BMO Capital Markets on Thursday, March 8. The stock rating was maintained by Wedbush with “Buy” on Monday, December 11. On Thursday, February 8 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given by Wedbush. The company rating was initiated by FBR Capital on Tuesday, March 27. On Monday, March 12 Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) with “Buy” rating. On Wednesday, December 20 Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating. Wedbush has “Buy” rating and $4.0 target. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On
20/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
11/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain

RGLS reached $0.71 during the last trading session after $0 change.Since May 17, 2017 it’s 52.76% down thus downtrending. RGLS underperformed the S&P 500 by 64.31%.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is valued at $74.07 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Last it reported negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Another two news for Regulus Therapeutics Inc. (NASDAQ:RGLS) were recently released by: on May 11, 2018 with title “Regulus Therapeutics’ (RGLS) CEO Joseph Hagan on Q1 2018 Results – Earnings Call Transcript”. The other‘s article was titled “Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global …” and released on May 17, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.